Physician profile
Madeline E Waters
NPI 1922486844
$12,843.39
in general payments reported to CMS, 2019-2025
61 companies · $3,687 in 2025
The $3,687 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $836 · 2023: $1,973 · 2024: $5,935 · 2025: $3,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,662 · Honoraria: $2,000 · Travel and Lodging: $926 · Education: $6.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,662.45 |
| Honoraria | $2,000.00 |
| Travel and Lodging | $926.17 |
| Education | $6.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $3,135.29 | 2024 | |
| Novartis Pharmaceuticals Corporation | $976.95 | 2021-2025 | Piqray, Kisqali |
| Daiichi Sankyo INC. | $748.38 | 2022-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $589.12 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Abbvie INC. | $495.91 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $456.80 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Glaxosmithkline, LLC. | $446.59 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $405.97 | 2022-2025 | |
| Genzyme Corporation | $373.51 | 2022-2025 | |
| Janssen Biotech, INC. | $313.77 | 2022-2025 | Erleada, Rybrevant, Darzalex |
| Regeneron Healthcare Solutions, INC. | $285.06 | 2022-2025 | Libtayo |
| Incyte Corporation | $258.63 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $250.22 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $247.39 | 2021-2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $232.06 | 2021-2025 | Onivyde |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $219.88 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Astellas Pharma US INC | $213.84 | 2022-2025 | Xtandi, Padcev |
| Celgene Corporation | $212.23 | 2021-2025 | Reblozyl |
| Kite Pharma, INC. | $188.58 | 2023-2025 | Yescarta |
| Array Biopharma INC | $186.96 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $177.63 | 2022-2025 | Alunbrig, Fruzaqla |
| Myriad Genetic Laboratories, INC. | $165.93 | 2022-2025 | Myrisk |
| E.R. Squibb & Sons, L.L.C. | $129.90 | 2023-2025 | Opdivo, Reblozyl, Augtyro |
| Eisai INC. | $128.78 | 2023-2024 | |
| Aveo Pharmaceuticals, INC. | $120.05 | 2022-2025 | Fotivda |
| Sobi, INC | $114.64 | 2023-2024 | |
| Pharmaessentia USA Corporation | $114.04 | 2023-2025 | Besremi |
| Stemline Therapeutics INC. | $103.92 | 2023-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $102.10 | 2023-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $98.26 | 2022-2023 | Xpovio |
| Taiho Oncology, INC. | $95.31 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $92.40 | 2023-2025 | Monoferric, Cosela |
| Dendreon Pharmaceuticals LLC | $85.07 | 2025 | Provenge |
| Janssen Scientific Affairs, LLC | $84.43 | 2023 | Balversa |
| Jazz Pharmaceuticals INC. | $79.95 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.27 | 2022-2025 | |
| Blueprint Medicines Corporation | $73.22 | 2023-2024 | Ayvakit |
| Csl Behring | $67.83 | 2022-2024 | Afstyla, Idelvion |
| Sumitomo Pharma America, INC. | $54.27 | 2023-2025 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $52.75 | 2021-2022 | |
| Genentech USA, INC. | $48.20 | 2023-2024 | Perjeta, Kadcyla, Phesgo |
| Deciphera Pharmaceuticals INC. | $47.89 | 2022-2023 | Qinlock |
| Tersera Therapeutics LLC | $41.21 | 2023-2025 | Zoladex |
| Tactile Systems Technology INC | $40.00 | 2022 | |
| Rigel Pharmaceuticals, INC. | $38.62 | 2024 | Tavalisse, Rezlidhia |
| Legend Biotech USA INC. | $35.49 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $33.19 | 2023 | Xarelto |
| Beigene USA, INC. | $32.74 | 2024 | Tevimbra |
| Kyowa Kirin, INC. | $28.76 | 2025 | |
| Novocure INC. | $28.31 | 2024 | Optune |
| Genmab U.S., INC. | $23.89 | 2024 | Epkinly |
| Delcath Systems | $23.58 | 2025 | Hepzato Kit |
| Exelixis INC. | $22.91 | 2024 | Cabometyx |
| Servier Pharmaceuticals LLC | $22.05 | 2024 | |
| Emd Serono, INC. | $21.60 | 2025 | |
| Iovance Biotherapeutics, INC. | $21.44 | 2025 | Amtagvi |
| Puma Biotechnology, INC. | $19.01 | 2025 | |
| Syndax Pharmaceuticals, INC. | $16.31 | 2025 | |
| Myovant Sciences INC. | $16.18 | 2022 | |
| Amgen INC. | $15.05 | 2023 | Nplate, Vectibix, Xgeva |
| Sun Pharmaceutical Industries INC. | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.